<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14086">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923505</url>
  </required_header>
  <id_info>
    <org_study_id>WI_COPD+HF+SDB_16-250</org_study_id>
    <nct_id>NCT02923505</nct_id>
  </id_info>
  <brief_title>Effect of Positive Airway Pressure Therapy on Hospitalization and Mortality in SDB Patients With Comorbid Chronic Obstructive Pulmonary Disease (COPD) or/and Heart Failure (HF)</brief_title>
  <official_title>Effect of Positive Airway Pressure Therapy on Hospitalization and Mortality in SDB Patients With Comorbid Chronic Obstructive Pulmonary Disease (COPD) or/and Heart Failure (HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wissenschaftliches Institut Bethanien e.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wissenschaftliches Institut Bethanien e.V</source>
  <brief_summary>
    <textblock>
      The aim of the study is to test the hypothesis that treatment of sleep disordered breathing
      (SDB) in patients with comorbid chronic obstructive pulmonary disease (COPD) and/or heart
      failure (HF) with positive airway pressure (PAP) is associated with reduced risk for
      hospitalizations and death, lower health care utilization, and greater cost-effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this retrospective analysis the health care utilization in patients with COPD and HF will
      be quantified. Data of patients who additionally underwent a polysomnography or polygraphy
      between 2012 and 2015 are taken into consideration. The data (risk for hospitalization and
      death, comorbidities, diagnosis and therapy of SDB, costs of health care utilization) will
      be collected 12 months before and 12 months after diagnosis of SDB.

      The patients' medical records will also be reviewed for compliance to treatment for SDB, and
      the patients will be classified as treated or untreated. The treated group will be divided
      into two subgroups: those with &quot;good adherence&quot; to PAP therapy (≥ 4 hours PAP use per night)
      and those with &quot;poor adherence&quot; to PAP therapy (&lt; 4 hours PAP use per night). Healthcare
      Utilizations, HF or COPD exacerbations and mortality will be identified by reviewing medical
      records, National database when available, or self-reported by patient or patient's family
      through phone interview or questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Healthcare Costs</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis-related Healthcare Costs</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to PAP therapy, (% days with usage &gt;=4h/night)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Sleep-Disordered Breathing</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>SDB+COPD</arm_group_label>
    <description>Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SDB+HF</arm_group_label>
    <description>Patients with sleep-disordered breathing and concomitant heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SDB+COPD+HF</arm_group_label>
    <description>Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>polygraphy or polysomnography</intervention_name>
    <arm_group_label>SDB+COPD</arm_group_label>
    <arm_group_label>SDB+HF</arm_group_label>
    <arm_group_label>SDB+COPD+HF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient from primary care clinics and sleep medicine centers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects between 21 to 75 years;

          -  consecutive patients who underwent polysomnography or polygraphy during the period of
             01/01/2012 to 31/12/2015.

          -  diagnosis of COPD and/or HF

        Exclusion Criteria:

          -  age &lt;21 or &gt;75 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcel Treml, Dr.</last_name>
    <phone>+49212636661</phone>
    <email>marcel.treml@klinik-bethanien.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Winfried J Randerath, Prof. Dr.</last_name>
    <phone>+49212636002</phone>
    <email>Randerath@klinik-bethanien.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Center for Sleep Medicine</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Poul J Jennum, Prof. Dr.</last_name>
      <phone>+45 38 63 25 12</phone>
      <email>poul.joergen.jennum@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble Alpes, Pole Thorax et Vaisseaux (PTV), Clinique de Physiologie Sommeil et Exercice</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean L Pepin, Prof. Dr.</last_name>
      <email>jpepin@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interdisziplinäres Schlafmedizinisches Zentrum, Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Penzel, Prof. Dr.</last_name>
      <phone>+49 30 450 513 013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schlafmedizinisches Zentrum der Klinik und Polyklinik für Innere Medizin II, Pneumologie, Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Arzt, Prof. Dr.</last_name>
      <phone>+49941944-7281</phone>
      <email>michael.arzt@schlaf-medizin.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wissenschaftliches Institut Bethanien für Pneumologie e.V.</name>
      <address>
        <city>Solingen</city>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcel Treml, Dr.</last_name>
      <phone>+49212636661</phone>
      <email>marcel.treml@klinik-bethanien.de</email>
    </contact>
    <investigator>
      <last_name>Winfried J Randerath, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
